NUVECTIS ANNOUNCES NXP200 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR BRAF V600-MUTANT, RECURRENT OR PROGRESSIVE, HIGH-GRADE GLIOMA

Reuters · 1d ago

Please log in to view news